Entamoeba histolytica is one of the most common parasitic infections worldwide, infecting about 50 million people and resulting in 40 000–100 000 deaths a year. In Australia, people at risk of infection include immigrants, travellers returning from countries of high endemicity, Indigenous people, and men who have sex with men. A sample of returned travelers who sought health care from 2007 through 2011 at any of 53 international GeoSentinel-associated clinics showed that most people diagnosed with E. histolytica had traveled for tourism to India, Indonesia, Mexico, or Thailand, as opposed to visiting with friends and relatives or traveling for business.
Molecular methods using the polymerase chain reaction amplify E. histolytica genes from extracted faecal DNA. Sensitivity and specificity are high. For symptomatic intestinal infection and extraintestinal disease, treatment with metronidazole or tinidazole should be followed by treatment with iodoquinol or paromomycin. Asymptomatic patients infected with E. histolytica should also be treated with iodoquinol or paromomycin.
Most patients have a gradual illness onset days or weeks after infection. Symptoms include cramps, watery or bloody diarrhea, and weight loss and may last several weeks.